News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Investor Alerts Year All Years 2022 2021 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard 01.07.2022 Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor Read More > 01.04.2022 Nuvalent to Present at the 40th Annual J.P. Morgan Healthcare Conference Read More > 11.10.2021 Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results Read More > 10.07.2021 New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC Read More > 09.08.2021 Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results Read More > Show 5102550100 per page«12345»
